Arcadia Biosciences (NASDAQ:RKDA) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a report issued on Saturday. The firm set a “sell” rating on the basic materials company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of Arcadia Biosciences in a report on Wednesday, August 21st.

Arcadia Biosciences Price Performance

Shares of RKDA opened at $2.72 on Friday. The firm has a market cap of $3.71 million, a P/E ratio of -0.53 and a beta of 1.34. Arcadia Biosciences has a 1 year low of $1.85 and a 1 year high of $3.93. The company has a 50 day simple moving average of $2.82 and a two-hundred day simple moving average of $2.68.

Arcadia Biosciences (NASDAQ:RKDA) last posted its earnings results on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share for the quarter, missing the consensus estimate of $1.27 by ($0.49). The company had revenue of $1.31 million for the quarter, compared to analysts’ expectations of $0.95 million. Arcadia Biosciences had a negative net margin of 127.29% and a negative return on equity of 57.51%. During the same period in the previous year, the business posted ($2.64) earnings per share. On average, sell-side analysts anticipate that Arcadia Biosciences will post -1.7 earnings per share for the current year.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.